Free Trial

Corvus Pharmaceuticals (CRVS) SEC Filings & 10K Form

Corvus Pharmaceuticals logo
$4.31 +0.18 (+4.36%)
Closing price 04:00 PM Eastern
Extended Trading
$4.22 -0.09 (-1.97%)
As of 05:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Corvus Pharmaceuticals SEC Filings

DateFilerForm TypeView
07/01/2025
8:17 PM
Corvus Pharmaceuticals (Issuer)
Thompson Peter A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2025
8:23 PM
Corvus Pharmaceuticals (Issuer)
ORBIMED ADVISORS LLC (Reporting)
OrbiMed Capital GP V LLC (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/06/2025
3:26 PM
Corvus Pharmaceuticals (Issuer)
Jones William Benton (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025
6:00 AM
Corvus Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/14/2025
7:49 PM
Corvus Pharmaceuticals (Subject)
ORBIMED ADVISORS LLC (Filed by)
Form SCHEDULE 13D/A
05/08/2025
4:30 PM
Corvus Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
05/01/2025
8:20 PM
Corvus Pharmaceuticals (Subject)
ORBIMED ADVISORS LLC (Filed by)
Form SCHEDULE 13D/A
04/09/2025
4:26 PM
Corvus Pharmaceuticals (Issuer)
van den Broek Richard (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
04/09/2025
4:26 PM
Corvus Pharmaceuticals (Issuer)
van den Broek Richard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/09/2025
3:21 PM
Corvus Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/14/2025
12:53 PM
Corvus Pharmaceuticals (Subject)
SAMLYN CAPITAL, LLC (Filed by)
Form SCHEDULE 13G/A
01/13/2025
6:30 AM
Corvus Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/23/2024
3:40 PM
Arcara Jeffrey (Reporting)
Corvus Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2024
3:38 PM
Corvus Pharmaceuticals (Issuer)
MILLER RICHARD A MD (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2024
3:39 PM
Corvus Pharmaceuticals (Issuer)
LEA LEIV (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2024
3:39 PM
Corvus Pharmaceuticals (Issuer)
Jones William Benton (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2024
6:30 AM
Corvus Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/23/2024
3:11 PM
Corvus Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/15/2024
11:15 PM
Corvus Pharmaceuticals (Filer)
Form EFFECT
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:CRVS) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners